An alert system compared with an already active app
The trial was conducted at two German university hospitals among adults with stage I to III breast cancer who were starting systemic treatment. Of the 605 people randomly assigned to the groups, 487 were included in the modified intention-to-treat analysis.
Both groups had the same ENABLE app, with educational resources, organizational support and scheduled quality-of-life assessments. The experimental group also received a weekly questionnaire, followed, depending on the responses, by symptom assessment, digital triage and alerts to the care team.
The comparison is therefore not between an app and no digital support. It seeks to isolate the added value of regular screening and the care team's response pathway.
Measurable but small differences
At the end of treatment, the group with alerts had a fatigue score 3.90 points lower, social participation 2.84 points higher and an anxiety score 2.10 points lower. These differences were statistically significant after correction for multiple comparisons.
However, the differences in standardized scores remained below the 5-point threshold considered minimally important in the study. A statistical difference is therefore not enough to establish a noticeable benefit for each person.
The results do not demonstrate improvement across all the dimensions assessed. After statistical correction, differences in depression, sleep disturbances, physical function and pain, among other measures, were not significant. No single criterion for overall success had been predefined.
A care pathway, not a standalone treatment
Of the 209 people monitored through the alert system, 160 triggered at least one alert. This finding highlights that the intervention also relies on a team able to receive and respond to reports, not just on the software.
The trial was open-label: participants knew which group they were in, which may influence subjective responses. The gap between the number randomized and the number analyzed also calls for caution, although the abstract does not allow all the reasons to be examined.
No adverse effects related to the intervention were identified. This demonstrates neither the absence of all risk nor an effect on cancer control or survival, which are not the outcomes reported here.
Limitations to keep in mind
PubMed abstract only; full text not consulted. Open-label trial, analysis limited to 487 of the 605 people randomized, and benefits below the chosen threshold for clinical importance. The precise follow-up duration, funding and conflicts of interest have not been verified in the dossier.
What we can take away
ENABLE supports a limited role for digital monitoring linked to care teams in some aspects of daily life during treatment. It demonstrates neither an overall improvement in quality of life nor the effectiveness of an app used alone.
Sources and provenance
- Real-Time Electronic Patient-Reported Outcome Monitoring With Digital Triage and Care-Team Integration in Early Breast Cancer: ENABLE Randomized Controlled Trial.
Source date: 2026-10-28.
Journal Article, Randomized Controlled Trial, Multicenter Study · Résumé PubMed uniquement, texte intégral non consulté